Europe/India/Near East USA Asia
Bachem AG Bachem Americas, Inc. Bachem Japan K.K.
Hauptstrasse 144 3132 Kashiwa Street AREA Shinagawa, 13F
4416 Bubendorf - Switzerland Torrance, CA 90505 - USA Tokyo 108-0075 - Japan
Tel +41 58 595 2021 Tel +1 888 422 2436 Tel +81 3 4405 3141
Fax +41 58 595 2040 Tel +1 888 4BACHEM Email sales.jp@bachem.com
Email sales.ch@bachem.com Fax +1 310 539 9428  
  E-mail sales.us@bachem.com  

HISTORY

Bachem - making history in peptide manufacturing for more than 40 years

History

  • Bachem began in 1971, when Peter Grogg founded Bachem Feinchemikalien AG with two employees in Liestal near Basel with the focus on peptide synthesis.
  • In 1977, Bachem moved with eight employees to near-by Bubendorf, and, in 1978, it manufactured, for the first time, peptides for use in medicine under cGMP guidelines. Between 1981 and 1991 Bachem tripled its production capacity and built an administration building, while the number of employees grew to 150.
  • In 1995, facilities were further expanded including the quality control department to a total of 168'000 sq. ft. (15'600 m2), and employees totaled 190.
  • Expansion into markets outside Europe began with the establishment of Bachem Bioscience, Inc. in Philadelphia, USA in 1987. To strengthen its presence in Europe, Bachem opened sales and marketing centers in Germany in 1988 and in France in 1993. In 1996 it acquired its largest competitor, Bachem, Inc., together with its subsidiaries in Germany and the United Kingdom. In June 1998, following a very successful IPO, Bachem's shares began to be publicly traded on the Swiss Stock Exchange.
  • The Group had total sales of CHF 96 million in 1998 and a headcount of 331 employees. In 1999 and 2000, a new administration building and a further production facility were respectively opened at the Bubendorf site.
  • With the acquisition of the San Carlos, California based Peninsula Laboratories, Inc. and its affiliate Peninsula Laboratories Ltd., United Kingdom in December 1999, Bachem extended its strong position in therapeutically active peptides into immunology, a domain with strong future promise. In August 2000, Peninsula Laboratories Europe Ltd. and Bachem (UK) Ltd. merged together to a single Bachem group affiliated company in the United Kingdom.
  • The acquisition of Sochinaz SA, a Swiss-based specialized manufacturer of active pharmaceutical ingredients in 2001, strengthened Bachem's expertise and once again expanded its manufacturing capabilities. The headcount of the Group grew at this time to 500 employees.
  • Reorganization of distribution was carried out in Germany and France as a result of the positive experiences gained with the realignment of the sales and marketing organization in the USA. As a result the subsidiary in France was closed at the end of 2002. The subsidiary in Germany was relocated from Heidelberg to Weil am Rhein, was renamed Bachem Distribution Services GmbH and is now responsible for all customers in the European Union.
  • In 2003, a holding structure was introduced to align the factual organization of the company with an appropriate legal structure and to support management structure adjustments, given by continued company growth requirements.
  • In 2007, Bachem aquired the Clinalfa® brand for Bachem's ready-to-use clinical trial materials and related services.
  • In 2010, Bachem commenced the partnership with Atheris laboratories offering the Melusine® range of research products for lead generation of new pharmaceutical candidates.
  • In 2010, the Bachem Group had total sales of CHF 152.9 million and a headcount of 668 employees.
  • In 2011, Bachem celebrates its 40th year as a producer of research ingredients and active pharmaceutical ingredients (APIs) for the pharmaceutical industry.
  • In 2013, GlyTech, Inc. (Kyoto, Japan) and Bachem AG (Bubendorf, Switzerland) informed that they have successfully co-developed a chemical synthesis of Interferon β-1a applicable for industrial scale. Interferon β-1a is a 166 amino acid long glycosylated protein and an approved drug substance to treat multiple sclerosis with a world market of more than $ 4 billion.
  • In 2014, Bachem the leading peptide manufacturer, and GlyTech Inc. (Kyoto, Japan), the world-leading developer of glycosylated drugs, announced that they have entered into a co-promotion agreement for GlyTech's glycosylation technology. As part of the agreement, Bachem will leverage its sales and marketing resources to enhance GlyTech's partnering efforts and GlyTech will promote Bachem as the partner of choice for manufacture of its glycopeptides and glycoproteins.
  • In 2015, Bachem acquired American Peptide Company, a US-based specialized manufacturer of peptides. APC provides a wide range of services from small-scale catalog business and custom synthesis to large-scale manufacturing under cGMP. The acquisition of APC strengthens Bachem's expertise and once again expands its manufacturing capabilities.
  • In 2016, operations commenced at the Group’s most modern building for R&D projects and small lot production in Bubendorf, Switzerland. With a total headcount of 1'022, the company’s workforce passed the 1'000 mark for the first time in its history.
  • In 2017, Bachem together with a customer accepted the Greener Reaction Conditions Award at a National Academy of Sciences ceremony in Washington, D.C. The award was given to recognize the development of a robust, cost-efficient and environmentally friendly manufacturing process for a peptide compound with regulatory approval. Bachem’s Center of Excellence in production of Research Chemicals in St. Helens, UK, has obtained ISO certification in 2018 and additional production and analytical labs have been built and equipped with state-of-the-art instruments.
  • In 2018, Bachem established a new entity in Tokyo, Japan named Bachem Japan K.K. This new local presence in Asia will strengthen project and customer support and drive further business growth in the Asian market.